News flash: Docs like e-promos

Look no further for more evidence that humanity is getting a little too, er, enamored with the internet. According to a study of pharma e-promotions, almost three-fourths of doctors said they'd just as soon talk with a computer than with a drug rep--and some even preferred the computer.

If this study is to be believed, it's clear why e-promotion is on the move. More than two-thirds of physicians said they had a positive attitude toward this type of interaction with drugmakers. Perhaps that's because they could do so at their leisure. Almost 70 percent said they did their e-promos in the evenings. Or perhaps it's just because they don't have to make conversation.

Plus, in a boon for drugmakers, docs tended to spend about 18 minutes on each e-promo. "Through ePromotion, physicians have more time to review product information and review disease state information at their own convenience--at night time or on the weekends," said Heather Alba, senior manager, promotional audits at SDI, which did the study. Add in the fact that e-promos are less expensive than in-person detailing, and you see why more drugmakers are going this route.

But are e-promos as effective at boosting drug sales? That's the subject for another study--one we'd really like to read. So get to it, folks.

- read the article at Medical Marketing & Media

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.